MONCYTE Health

Fantastic news! 🔥

MONCYTE Health secures EUR 1 million capital to advance personalized treatment for high cholesterol. The investment round was led by Finnish venture capital investors Inventure, Almaral and Athensmed and included funding from University of Helsinki Funds, private European investors, and a grant from Business Finland. Read more here: https://lnkd.in/d8SBYKhX #moncytehealth #moncyte #investment #cardiovascular #highcholesterol

Cardiovascular disease is #1 cause of death worldwide. This #WorldHeartDay, sign the first global petition to prioritize heart health: https://bit.ly/3TrCzRT

It is a great honor to be part of a webinar about the differences between high cholesterol and familial hypercholesterolaemia organized by FH Europe Foundation! Thank you! Happy FH Awareness day! University of Helsinki | FH Europe Foundation | Moncyte https://lnkd.in/dQrguM9n

Absolutely amazing experience at #ESCCongress2024. Discussing Moncyte technology, meeting friends and experts, plus getting updates on all the new developments! Really great to be in #London! Tamara A. | Moncyte

We are excited to announce that Iris Lähdeniemi, Ph.D. joins the Moncyte team as Laboratory and Data Manager! 🔥 Iris is a cell biologist and has defended her PhD at Åbo Akademi University in 2018. She has a background in translational research and has worked at Institute for Molecular Medicine Finland and University of Helsinki for the past 5 years specializing in therapeutic targeting of patient cells. Iris is a proactive, curious and positive person and a great addition to the team working on bringing our novel technology for the benefit of patients with high cholesterol. Welcome to Moncyte, Iris! #moncyte #teammoncyte #cardiovascular #highcholesterol #biotech #diagnostics

We are excited to announce that Iris Lähdeniemi, Ph.D. joins the Moncyte team as Laboratory and Data Manager! 🔥 Iris is a cell biologist and has defended her PhD at Åbo Akademi University in 2018. She has a background in translational research and has worked at Institute for Molecular Medicine Finland and University of Helsinki for the past 5 years specializing in therapeutic targeting of patient cells. Iris is a proactive, curious and positive person and a great addition to the team working on bringing our novel technology for the benefit of patients with high cholesterol. Welcome to Moncyte, Iris! #moncyte #teammoncyte #cardiovascular #highcholesterol #biotech #diagnostics

✨ Exciting news: A new spinout company Moncyte from the University of Helsinki is transforming cholesterol treatment! 💫 Moncyte is revolutionising the treatment of high cholesterol. With their patented technology, Moncyte is paving the way for personalised medicine, ensuring that patients achieve their cholesterol goals faster and more effectively. 💡 Innovation: Unlike traditional diagnostic tests, Moncyte’s helps to facilitate the planning and implementation of personalised drug therapies in the treatment of high cholesterol. This helps to reduce cardiovascular risks and healthcare costs. 🌍 Entering a new market: Moncyte is not just a product; it’s a game-changing diagnostic test for clinics, health centres, and research facilities worldwide. 🥼 A strong foundation: Moncyte's leadership, led by Tamara Alagirova and Simon Pfisterer, brings extensive experience in medicine, diagnostics, pharmaceuticals and medical devices. 🚀 Helsinki Innovation Services Ltd is proud to have had the opportunity to accompany and support the Moncyte team on their commercialisation journey from a research project to a market credible spinout company. We wish Moncyte the best of luck in bringing personalised healthcare and a healthier future!

Raising awareness of Lp(a)! 🔥 Why is this important? 1️⃣ in 5️⃣ people worldwide are at increased risk of atherosclerotic cardiovascular disease due to a high Lp(a) level. It is recommended to measure Lp(a) at least once during an individual’s life. However, this is often overlooked in clinical practice. As Lp(a) concentration interacts with other risk factors to increase global cardiovascular risk, failure to take the Lp(a) level into account can underestimate this risk. High Lp(a) is associated with vascular inflammation, but not all people with high Lp(a) are at high risk of cardiovascular disease (CVD). There is also an important notion of biological variability between individuals. Moncyte sheds light on cellular processes linked to CVD progression, inflammation and monocyte plaque infiltration, and can identify individuals with high-residual risk on standard lipid-lowering therapy in need of more effective medication. 🔥

Very informative and touching real life stories from people with life threatening genetic conditions reducing the ability of cells to remove LDL cholesterol from the bloodstream, causing super high cholesterol levels and increasing the risk of cardiovascular disease in early childhood. Managing fear, worry, lack of information, very strict diet, treatments, open heart surgeries and receiving a scary diagnosis for a 2 years old child can be extremely challenging for parents as well as children and affect psychological wellbeing throughout life. We need to foster understanding, support, communication and empathy that are very important for families affected by these conditions, and Moncyte is proud to support FH Europe Foundation on this journey! 🔥 Magdalena Daccord | Maria NASSIF | Chyrel Lichaa | Jill Prawer | Finian Day-Lewis CAE AMIMI | Michelle Watts | Natalia Vázquez | Patsy Petrie Assoc CIPD |